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Abstract: Although Neuregulin-1 (Nrg1) and its cognate receptors have been found at the mRNA level in hu-
man gastrointestinal (GI) tract and their functional roles have been evaluated in vitro, their morphological
distribution in higher mammals are not fully elucidated. The present research focused on morphological distri-
bution of Nrg1 and its receptors, ErbB2 and ErbB4, in main GI tissues of the non-human primate rhesus mon-
key. The morphological expression of Nrg1 and its ErbB2 and ErbB4 receptors as well as their potential co-
localization were determined by double immunofluorescence staining in esophagus, stomach, small intestine
and colon tissues derived from the rhesus monkey tissue microarray. The Nrg1 level on each sample was indexed
by the fold of integrated fluorescence intensity (IFI) relative to that of one brain cortical tissue from the rhesus
monkey. Differential expression of Nrg1 and its receptors ErbB2 and ErbB4 was found in the GI structures, with
higher expression levels detected in stomach and small intestine. Co-localization of Nrg1 with ErbB2 and/or
ErbB4 receptors was most apparently detected in the stomach, followed by small intestine, colon, and esopha-
gus. This investigation morphologically profiles the differential expression of Nrg1 and its receptors in main GI
structures, suggesting an autocrine or paracrine loop-directed Nrg1/ErbB receptor signaling pathway in these
organs of higher mammals. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 1, 38–44)
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Introduction
Neuregulin-1 (Nrg1) is one of the most active mem-
bers of the epidermal growth factor (EGF)-like fam-
ily [1]. As a result of the alternative splicing of NRG1
gene, at least six isoforms of Nrg1, including type I to
III Nrg1a and Nrg1b, have been identified [2]. In the
developing brain Nrg1 was observed in the gray mat-
ter of cortex, hypothalamus and cerebellum. In the
adult brain, expression of Nrg1 was observed in more
extensive brain areas, including the hypothalamus,
hippocampus, basal ganglia and brain stem [3, 4]. In-
teraction of Nrg1 with the dimers of its receptors, in-
cluding ErbB2, ErbB3, and ErbB4, results in many
biological processes [5, 6]. Receptors of Nrg1 were
reported to be expressed in the hypothalamic astro-
cytes, where their activation as a result of paracrine
Nrg1 stimulation leads to the secretion of luteinizing
hormone-releasing hormone [3, 4]. Recently, Nrg1
was also detected in gonadotroph cells of the anteri-
or pituitary, where it is assumed to mediate prolactin
secretion from the lactotrophs in a juxtacrine man-
ner [7, 8]. Nrg1 also promotes the invasive behavior
of breast cancer cells in vitro, thus enhancing meta-
static processes by regulating actin cytoskeleton
through autocrine or paracrine mechanism [9, 10].
ErbB receptors and other ErbB ligands including
epiregulin, epidermal growth factor (EGF), heparin-
binding EGF, transforming growth factor alpha
(TGFa) and neuroglycan-C were expressed in gas-
tric and colon cell lines [11]. Similar expression pat-
tern was also demonstrated in colorectal carcinomas,
forming receptor/ligand system involved in cancer de-
velopment and progression as a prognostic indicator
[12]. Although a higher expression of epidermal
growth factor receptor (EGFR) was associated with
increased invasiveness, reduced survival rate and poor
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prognosis in patients with colorectal carcinoma, little
is known about the distribution and functions of
ErbB2 and ErbB4 in the GI tract [12].
In the rhesus monkey (Macaca mulatta), in vivo
therapeutic effects of Nrg1 were investigated in mul-
tiple disease models [13], such as pacing-induced heart
failure [14] in which recombinant Nrg1 increased ac-
tivity of PKB and Bcl-xl protein and exerted effects
on left ventricular volume of healthy Macaca mulatta,
with no significant effect on cardiac contractility [15].
In addition, widespread expression of ErbB2, ErbB3
and ErbB4 receptor mRNAs throughout telencep-
halon was observed in juvenile and adult Macaca
mulatta [16]. However, no morphological expression
of Nrg1 was described in the GI system of rhesus
monkey.
Since many neuropeptides have been found along
the wall of the gastrointestinal (GI) tract we decided
to investigate the morphological expression of Nrg1
and its specific ErbB2 and ErbB4 receptors in the
major organs of the GI system. The reported find-
ings may increase our understanding of the Nrg1/ErbB
receptor signaling-based functions in the GI tract.
Material and methods
Mouse anti-Nrg1a/b antibodies were purchased from Lab
Vision (Fremont, CA, USA). Rabbit anti-ErbB2 and ErbB4
antibodies were purchased from Beijing Biosynthesis Bio-
technology (Beijing, China). Donkey anti-goat secondary
antibody conjugated to DylightTM 488 and donkey anti-rab-
bit secondary antibody conjugated to DylightTM 594 were
purchased from the Jackson Laboratory (Jackson Labs, Bar
Harbor, ME, USA). The Macaca mulatta tissue microarray
was obtained from Chaoying Biotechnology (RhFDA1,
Xi’an, Shaanxi, China).
Paraffin embedded 4 mm-thick tissue sections of the major
GI organs were dewaxed, and antigen retrieval was per-
formed using 10 mM citrate buffer (pH 6.0 in a 99°C water
bath for 40 min. Samples were blocked with 10% normal
donkey serum (NDS) and incubated overnight at 4°C with
the following primary antibodies: mixture containing mouse
monoclonal anti-Nrg1 a/b (1:100) and rat anti-ErbB2 or rat
anti-ErbB4 antibodies (1:100). After being washed, sam-
ples were incubated at room temperature with donkey anti-
mouse antibody conjugated to DylightTM 488 and donkey
anti-rabbit antibody conjugated to DylightTM 594 (1:500 for
both). Nuclei were counterstained with DAPI. Images were
acquired using a Zeiss Microscopy system (Axio Imager Z1,
Zeiss, Germany). DAPI was excited at 405 nm, DylightTM
488 at 488 nm, and DylightTM 594 at 594 nm in a multi-track
configuration. In addition, one dewaxed tissue microarray
was subjected to hematoxylin and eosin (H&E) staining for
basic morphological observations.
Integrated fluorescence intensity (IFI) was used to evalu-
ate the protein levels of Nrg1 on the GI tissue points. The
IFI for Nrg1 at each tissue point was obtained using the
MultiImageTM Light Cabinet CY3 of the FluorChem HD2
gel imaging system (Alpha Innotech, CA, USA), and the
IFI indexed by the optical density was analyzed using Im-
age Tool II software (University of Texas Health Science
Center, San Antonio, TX, USA). The IFI was evaluated on
the basis of a gray scale ranging from 0-255, and was de-
fined as the fold of the IFI of each GI structure relative to
that of the brain cortical tissue.
Results are expressed as means ± SD based on data
obtained from at least 3 samples per group. Data were ana-
lyzed by independent sample t tests and p < 0.05 was con-
sidered statistically significant [17, 18].
Results
To evaluate the protein levels of Nrg1 in different
structures of the GI tract, integrated fluorescence
intensity (IFI) of Nrg1 signals were measured as de-
scribed in Methods. The relative expression was de-
termined by comparing the optic intensity with that
of the randomly selected brain cortex as a baseline
control. The relative protein presence of Nrg1 in
the esophagus, stomach, small intestine and colon tis-
sues were 0.32 ± 0.09, 1.26 ± 0.28, 1.37 ± 0.14 and
0.66 ± 0.12, respectively (Figure 1). Relative Nrg1
IFI in the stomach and small intestine was significantly
higher than those in the esophagus (p < 0.01 for both)
and in the colon tissues (both p < 0.05). Relative Nrg1
IFI in the colon tissues was also significantly higher
than that in the esophagus (p < 0.05). No significant
difference was found in the relative Nrg1 IFI between
stomach and small intestine.
Basic esophagus structure based on H&E stain-
ing was shown in Figure 2A. In the wall of esophagus,
Nrg1 (Figure 2C) and ErbB4 (Figure 2D) were found
to be localized in the stratified squamous epithelial
(SSE) cells bordering the lamina propria (LP). In
addition, the two molecules were partially localized
there, and their staining in other esophagus structure
was relatively weak (Figure 2E, F). In contrast, we
were unable to detect presence of the ErbB2 recep-
tor (data not shown).
Basic gastric structure based on H&E staining was
shown in Figure 3A. In the stomach, Nrg1 was main-
ly observed in both the parietal cells predominating
in the mid and upper regions of the glands (Figure
3C, G), where both ErbB2 (Figure 3D) and ErbB4
(Figure 3H) receptors were expressed and co-local-
ized with Nrg1 individually (Figure 3E, I). In contrast,
the chief cells predominating in the lower region of
the gland only expressed Nrg1 ligand (Figure 2B, G).
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Basic morphology of the small intestine based on the
H&E staining was shown in Figure 4A. In the small
intestine samples, Nrg1 was selectively expressed in
a small population of cells in the lamina propria
(Figure 4C, G), whereas ErbB2 was barely detected
(Figure 4D, E). In contrast, ErbB4 could be observed
in similar cells (Figure 4H), where it co-localized with
Nrg1 (Figure 4I). These cells were in morphology and
localization similar to the enteroendocrine (EE) cells,
which were also indicated in the inset in Figure 4A.
Basic morphology of the colon tissue based on
H&E staining was shown in Figure 5A. In the colon,
Nrg1 was selectively and weakly localized on the mem-
brane of the absorptive columnar cells (Figure 5C, G),
whereas ErbB2 (Figure 5D) and ErbB4 (Figure 5H)
were almost undetectable. And no co-localization of
Nrg1 and ErbB2 (Figure 5E) and ErbB4 (Figure 5I)
was found.
Discussion
Although expression, localization and functions of
Nrg1 and its receptors were described in various tis-
sues and organs, their morphological distribution and
localization in the main parts of the GI tract of the
Macaca mulatta have not been well elucidated. This
prompted us to investigate the expression and local-
ization of Nrg1 and ErbB2/ErbB4 in the GI tissues of
this non-human primate. The main findings showed
differential expression and distribution of Nrg1 and
its cognate receptors in the GI tract, with higher ex-
pression of Nrg1, ErbB4 and/or ErbB2 in the stom-
ach and the small intestine.
In one study of the human upper GI mucosa bi-
opsy specimen, type I Nrg1, ErbB3 and ErbB4 mRNA
were detected in esophagus, stomach and duodenum
with the highest expression found in duodenum [19].
These findings suggested the physiological signifi-
cance of Nrg1 and its receptors in the human upper
GI mucosa. However, cells expressing Nrg1 and ErbB
receptors were not further identified. Compared with
RT-PCR, immunofluorescence-based investigation
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Figure 1. Comparison of Nrg1 integrated immunofluore-
scence intensity (IFI) in main gastrointestinal tract.
Abbreviations. C — control, E — esophagus, S — stomach,
SI — small intestine, CO 0 — colon.
ap < 0.01 compared to values in the esophagus group;
bp < 0.05 compared to values in the colon group; cp < 0.05
compared to values in the esophagus group
Figure 2. Expression and localization of Nrg1 and ErbB4 in the Rhesus monkey esophagus tissue. A. H&E staining;
B. DAPI staining of cell nuclei (blue); C. expression of Nrg1 (green); D. expression of Erb4 (red); E. co-localization of Nrg1
and Erb4 (yellow); F. magnified insert from E. SSE: stratified squamous epithelium; LP: lamina propria. Scale bars = 50 mm
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Figure 3. Expression and localization of Nrg1, as well as ErbB2/ErbB4 in the Rhesus monkey gastric tissue. A. H&E
staining; B and F. DAPI staining of cell nuclei (blue); C and G. expression of Nrg1 (green); D. expression of ErbB2 (red);
E. co-localization of Nrg1 and Erb2 (yellow); H. expression of ErbB4 (red); I. co-localization of Nrg1 and Erb4 (yellow).
M: mucosa; PC: parietal cell; CC: chief cell. Scale bars = 50 mm
Figure 4. Expression and localization of Nrg1, as well as ErbB2/ErbB4 in the Rhesus monkey small intestinal tissue.
A. H&E staining; B and F. DAPI staining of cell nuclei (blue); C and G. expression of Nrg1 (green); D. expression of ErbB2
(red); E. co-localization of Nrg1 and Erb2 (yellow); H. expression of ErbB4 (red); I. co-localization of Nrg1 and Erb4
(yellow). The arrow indicates a cell, which is morphologically similar to the enteroendocrine (EE) cell. Scale bars = 50 mm
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can clarify in detail the distribution of Nrg1 and ErbB
receptors and types of cells expressing them. Here,
Nrg1 and ErbB2/ErbB4 receptors were sparsely and
weakly expressed in the esophagus and colon tissues,
which may suggest that they are not functionally vital
in these tissues. However, both common and rare
variants of the NRG1 gene have been reported to
contribute to Hirschsprung disease (HSCR, congen-
ital colon aganglionosis), a relatively common com-
plex genetic condition caused by abnormal develop-
ment of the enteric nervous system (ENS) [20].
In the investigated GI tissues, the highest level of
Nrg1 was observed in the stomach and the small in-
testine, suggesting that physiological autocrine/juxta-
crine interaction of Nrg1 with their receptors may
exert specific, even if unknown, functions in the up-
per GI tract. In contrast to the low level in the small
intestine tissue, the staining intensity of ErbB2 was
the same to that of ErbB4 receptor in parietal cells
which predominated in the mid and upper regions of
gastric and small intestinal glands. These observations
may suggest possibility of the formation of ErbB2/
/ErbB4 heterodimeric complex and their involvement
in the autocrine signaling initiated by Nrg1 in the gas-
tric structures, while the ErbB4/ErbB4 homodimeric
complex may predominately exist in the small intes-
tine tissue. Nrg1-stimulated heterodimerization rep-
resents a key feature of mitogenic signaling in mam-
mary epithelial cells and tumors, including cell pro-
liferation, differentiation and migration, and malig-
nant transformation [21, 22]. It was found that in
various cells ErbB2 can preferentially form het-
erodimers with both EGFR, as well as with ErbB3
and ErbB4 [23, 24].
The balance of ErbB4/ErbB4 homodimers versus
its heterodimeric complexes with other EGFR fami-
ly members determines cell proliferation or differen-
tiation. Introduction of ErbB4 in ErbB4-negative
SUM102 cells resulted in cell differentiation and was
both necessary and sufficient to trigger an antiprolif-
erative response in human breast cancer cells [24].
Recently, somatic mutations altering the coding re-
gion of ErbB4 were described in patients with gastric
and colorectal cancer [25]. Considering the hydrochlo-
ric acid secretion function of the parietal cells, we
hypothesize that the abundant expression of Nrg1 and
ErbB2/ErbB4 may function by protecting the self-
damage of cells by hydrochloric acid and may modu-
late the parietal cell differentiation and renewal. Nrg1
ligation to ErbB4 promotes its heterodimerization
Figure 5. Expression and localization of Nrg1, as well as ErbB2/ErbB4 in the Rhesus monkey colon tissue. A. H&E staining;
B and F. DAPI staining of cell nuclei (blue); C and G, Nrg1 was found in a main population of the absorptive columnar
cells (green); D. expression of ErbB2 (red); E. co-localization of Nrg1 and Erb2 was undetectable; H. expression of ErbB4
(red); I. co-localization of Nrg1 and Erb4 was not detected. Scale bars = 50 mm
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with ErbB2, and consequent ErbB2 tyrosine phospho-
rylation, thus affecting colon cancer growth [26]. It
has been reported that ErbB2 and ErbB3, but not
ErbB4, were expressed in gastric cancer cell lines, with
their cognate ligand Nrg1a in gastric fibroblasts [27].
Thus, a mesenchymal-epithelium-based paracrine
activation of intracellular signal pathway may exist in
the gastric mucosa. It was found that EGF can in-
duce cell growth and differentiation in the absence
of EGFR to form a heterodimer between ErbB3 and
ErbB2, a previously identified oncogenic complex in
response to EGF and betacellulin [28]. In some oth-
er conditions, activation of ErbB2 was the result of
Nrg1-mediated interaction with ErbB3 and it gener-
ated downstream activation of the ERK and the phos-
phatidylinositol 3'-kinase (PI3K)/AKT pathways [29].
However, Tsai et al. [30] reported that blocking Nrg1
expression suppressed the aggressive phenotype of
MDA-MB-231 breast cancer cells, as evidenced by
inhibited cell proliferation, anchorage-independent
growth failure and the suppression of the cell inva-
sion. This suggests that Nrg1 can function indepen-
dent of ErbB2 overexpression.
Based on the observation about the presence of
ErbB4 and the absence of ErbB2 in the cells of the
small intestine, it may be concluded that ErbB4 ho-
modimers represent the predominant functional ErbB
receptor pattern in this part of the GI tract. Zhao
and colleagues [6, 7] reported that Nrg1 can induce
PRL secretion from rat lactosomatotroph GH3 cells
in either an autocrine or a paracrine manner in vitro,
suggesting that Nrg1 may possibly be responsible for
hormone production and secretion in the small intes-
tine. Although ErbB4 was absent in the colon tissue,
high levels of ErbB4 receptors were observed in hu-
man and mouse colitis [31]. Increased ErbB4 expres-
sion synergizes with proinflammatory cytokines to
upregulate COX-2 expression and to inhibit colon
epithelial apoptosis. Such a process may be involved
in the development of tumorigenesis [31]. In vitro,
Nrg1 acts to stimulate the proliferation and alters the
cellular morphology of colonic epithelial cells in cul-
ture, with Nrg1b exhibiting more pronounced effects
than the alpha isoform [32]. NRG4 and ErbB4 were
also found to be mainly expressed in mucosa-associ-
ated lymphoid tissue (MALT) and follicular lympho-
ma, where they function in the proliferation of ma-
lignant lymphoma cells in the GI tract [33]. Thus, ex-
pression of Nrg1 in the colon may also regulate growth
and differentiation of colonic epithelial cells under
pathologic conditions.
EGF receptor family members including EGFR
and ErbB2 are main candidates for the molecular-tar-
geted therapy of gastric cancer and colon cancer due
to their overexpression [34]. Blockade of ErbB2 acti-
vation by Nrg1 neutralizing antibodies prevented cell
cycle re-entry and reduced Nrg1b1-induced migration
and invasion and also induced apoptosis in colon can-
cer cell lines [29, 34]. Neutralization of Nrg1 function
also abolished radiation-induced AKT activation and
reverted the radiosensitivity of HCT116 colorectal car-
cinoma cells to a lower level [35]. In addition, anti-
ErbB2 monoclonal antibody 2C4 can block Nrg1-stim-
ulated phosphorylation of ErbB2 and ErbB3, activa-
tion of mitogen-activated protein kinase (MAPK),
PI3K, and Akt, accompanied with inhibited prolifera-
tion and anchorage-independent growth [36].
In conclusion, we observed the preferential expres-
sion of Nrg1 with their receptors ErbB4 and/or ErbB2
in the gastric and small intestinal tissues, supporting
the autocrine role of Nrg1 in modulating cell differ-
entiation and proliferation through ErbB4/ErbB4
homodimers and ErbB4/ErbB2 heterodimers in these
regions. These observations require further studies
to explore the role of Nrg1 and its receptors in the
pathogenesis of the GI tract diseases.
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